Angiotensin II type 1 receptor blockade: High hopes sent back to reality?

Minerva Cardioangiologica

Volumn 57, Issue 6, 2009, Pages 773-785

  Grothusen, C ^a   Divchev, D ^a   Luchtefeld, M ^a   Schieffer, B ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiotensin II type 1 receptor blockers; Cardiovascular diseases; Diabetes mellitus; Renin angiotensin system

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; IRBESARTAN; LOSARTAN; NITRENDIPINE; PLACEBO; RAMIPRIL; SARALASIN; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; VASODILATOR AGENT;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC HEART FAILURE; GLUCOSE TOLERANCE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SYSTOLIC HEART FAILURE;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CONSENSUS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SARALASIN; SECONDARY PREVENTION; STROKE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 77949576187     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998;98:73-81.
2. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.
3. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1177-81.
4. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999;20:1182-90.
5. Pals DT, Masucci FD, Sipos F, Denning GS, Jr. A specific competitive antagonist of the vascular action of angiotensin. II. Circ Res 1971;29:664-72.
6. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
7. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-9.
8. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.
9. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
10. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008;121:656-63.
11. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008:CD003822.
12. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
13. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
14. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
15. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
16. Lindholm LH. Valsartan treatment of hypertension - does VALUE add value? Lancet 2004;363:2010-1.
17. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I et al. Randomised trial of losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
18. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
20. Baguet JP, Barone-Rochette G, Neuder Y. Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag 2009;5:257-64.
21. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
22. Mitchell GF, Arnold JM, Dunlap ME, O'Brien TX, Marchiori G, Warner E et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. Eur J Heart Fail 2006;8:191-7.
23. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67.
24. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart FaUure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
25. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
26. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
27. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:210-47.
28. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703.
29. Strauss MH, Hall A. Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings: no. Stroke 2009;40:3161-62.
30. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-633.
31. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-449.
32. Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract 2007;76(Suppl 1):S3-12.
33. Association AD. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29(Suppl)S4-S42.
34. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004;30:498-505.
35. Andraws R, Brown DL. Effect of inhibition of the reninangiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99:1006-12.
36. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl 1):S13-61.
37. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560-2572.
38. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;42(6 Suppl 5):A5-7, S1-230.
39. Bidani AK, Griffin KA. Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens 2002;11:73-80.
40. Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008;51(1 Suppl 1):S1-320.
41. Dzau V. The cardiovascular continuum and reninangiotensin-aldosterone system blockade. J Hypertens Suppl 2005;23:S9-17.
42. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
43. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
44. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
45. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
46. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
47. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12-154.